01

ABOUT JUPITER NEUROSCIENCES

We’re a clinical-stage drug platform company focused on treating neuroinflammation.

Our mission is making a significant impact for patients and society through a safe and oral medication for Alzheimer’s disease and for people with rare diseases.

02

Management

Strong management with extensive international experience and a track record for successfully building organizations that can take a product from inception to commercialization.

Christer Rosén

Founder, Chairman & CEO

Dana Eschenburg Perez, CPA

CFO

Marshall Hayward, Ph.D.

Co-Founder, CSO

Alexander Rosén

Co-Founder, CAO

Alison D. Silva

President & CBO

Dr. Claes Wahlestedt, MD, Ph.D.

Co-Founder, Consulting CMO

Shaun P Brothers, Ph.D.

Co-Founder, Consulting Head of Scientific Research

03

Board of Directors

Advisors combining expertise across industry, drug development, advocacy, and the investment community, unified by our mission to make a significant impact in neurological disorders, including Alzheimer’s, and multiple rare diseases.

Christer Rosén

Founder, Chairman & CEO

Marshall Hayward, Ph.D.

Co-Founder, CSO

Alison D. Silva

President & CBO

Nicholas Hemmerly

Julie Kampf

Holger Weis, CPA

Allison W. Brady

04

Scientific Advisory Board

Scientific team comprising of world-renowned specialists in their respective fields, providing hands-on involvement and valuable assistance to Jupiter Neurosciences.

Dr. Claes Wahlestedt, MD, Ph.D.

Co-Chairman

Rudolph Tanzi, Ph.D.

Co-Chairman

Li- Huei Tsai, Ph.D.

Scientific Advisor

Raymond Scott Turner, MD, Ph.D.

Scientific Advisor

Charbel Moussa, MBBS, Ph.D.

Scientific Advisor

Peter Elliott, Ph.D.

Scientific Advisor

W. Dalton Dietrich, III, Ph.D.

Scientific Advisor

Our Partners

Partner with the best

Join our mission to develop a treatment for Alzheimer’s disease and rare neurological disorders.